We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New Prenatal Cystic Fibrosis Tests Improve CFTR Screening Options

By LabMedica International staff writers
Posted on 03 Nov 2014
Print article
Image: The cystic fibrosis transmembrane conductance regulator (CFTR) channel protein controls the flow of H2O and Cl- ions into and out of lung cells. When CFTR is working correctly (Panel 1), these ions flow in and out. However, when CFTR is malfunctioning (as in Panel 2), these ions cannot flow out of the cell due to channel blockage, leading to the buildup of thick mucus in the lungs characteristic of cystic fibrosis (Photo courtesy of Wikimedia (user Lbudd14)).
Image: The cystic fibrosis transmembrane conductance regulator (CFTR) channel protein controls the flow of H2O and Cl- ions into and out of lung cells. When CFTR is working correctly (Panel 1), these ions flow in and out. However, when CFTR is malfunctioning (as in Panel 2), these ions cannot flow out of the cell due to channel blockage, leading to the buildup of thick mucus in the lungs characteristic of cystic fibrosis (Photo courtesy of Wikimedia (user Lbudd14)).
A new set of prenatal cystic fibrosis (CF) screening tests offer flexibility and comprehensiveness in screening for important CFTR gene variants.

Through its Institute for Biomarker Research division, Medical Diagnostic Laboratories, LLC (MDL; Hamilton, NJ, USA) is now offering a new CF testing option that utilizes cutting-edge technology, including next-generation sequencing (NGS) platforms. MDL, a member of the Genesis Biotechnology Group, is a CLIA-certified, CAP-accredited laboratory that specializes in high-complexity, state-of-the-art, automated DNA-based molecular analyses.

More than 1,800 different mutations have been discovered since the cystic fibrosis transmembrane conductance regulator (CFTR) gene responsible for CF (also called mucoviscidosis) was discovered in 1989. Offering CF carrier screening to all pregnant women as well as for preconception evaluation is now commonplace and formally recommended. Newborn screening for CF does not replace maternal-carrier screening. Screening is most efficacious in the non-Hispanic Caucasian and Ashkenazi Jewish populations.

Utilizing updated technologies, including NGS, MDL offers a diverse panel with high accuracy genetic testing that provides noninvasive, easy specimen collection methods for CF testing using mouthwash samples or cervico-vaginal swabs. Blood is also an acceptable source.

The MDL "Cystic Fibrosis Core Test" is a CFTR gene sequence analysis that screens for the 23 major mutations recommended by the American College of Medical Genetics (ACMG) and the American College of Obstetricians and Gynecologists (ACOG). The MDL "Cystic Fibrosis Comprehensive Test" is an expanded analysis that screens for 191 CFTR gene variants, including the recommended 23 major mutations and the 9 mutations recommended by the US Food and Drug Association (FDA) for determining Ivacaftor (Kalydeco) treatment efficiency. The MDL "Cystic Fibrosis Site Specific Analysis" screens for known family CF mutations previously identified in blood relatives.

Related Links:

Medical Diagnostic Laboratories


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.